Compare PL & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PL | LQDA |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.5B |
| IPO Year | 2021 | 2020 |
| Metric | PL | LQDA |
|---|---|---|
| Price | $13.10 | $39.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | $30.27 | ★ $54.38 |
| AVG Volume (30 Days) | ★ 8.6M | 4.7M |
| Earning Date | 12-09-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | N/A | ★ 1.26 |
| Revenue | ★ $307,727,000.00 | $158,320,000.00 |
| Revenue This Year | $42.22 | $357.27 |
| Revenue Next Year | $30.36 | $1.34 |
| P/E Ratio | ★ N/A | $30.82 |
| Revenue Growth | 25.94 | ★ 1031.18 |
| 52 Week Low | $10.52 | $22.05 |
| 52 Week High | $51.72 | $93.61 |
| Indicator | PL | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 29.66 | 43.19 |
| Support Level | N/A | $35.00 |
| Resistance Level | $18.49 | $40.60 |
| Average True Range (ATR) | 0.78 | 2.80 |
| MACD | -0.20 | 1.92 |
| Stochastic Oscillator | 2.44 | 96.06 |
Planet Labs PBC is an Earth-imaging company. It uses space to help life on Earth by imaging the world every day and making change visible, accessible, and actionable. Its platform includes imagery, insights, and machine learning that empower companies, governments, and communities around the world to make timely decisions about the evolving world. Its solutions are Broad Area Management. Its products are Planet Monitoring, Planet Tasking, Planet Analytic Feeds, Planetary Variables, Planet Basemaps, Planet Insights, and Platform Pricing. The group provides solutions to the Agriculture Science Program, Energy & Infrastructure, Forestry & Land Use, Mapping, Sustainability, Maritime, Civil Government, U.S. State and Local, Europe, Planet Federal, Defense & Intelligence, and Armed Services.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.